Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | NVO Novo Nordisk A/S | ABBV AbbVie |
|---|---|---|
| Price | $37.40 -1.3% | $259.93 -0.6% |
| StockIQ Score | 32F Weak Risk: High | 48D+ Moderate Risk: High |
| Technical | 6F | 41D |
| Fundamental | — | 57C |
| Growth | — | 34F |
| Fair Value | — | 33F |
| News | 92A+ | 98A+ |
| Quality | — | 42D |
| Risk | 42D | 44D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
AbbVie outperforms Novo Nordisk in nearly every category. Its investor score (48 vs. 32) and rating (Moderate vs. Weak) are stronger. AbbVie also leads in technical (41 vs. 6), fundamental (57 vs. unavailable), growth (34 vs. unavailable), and valuation (33 vs. unavailable) scores, showing broader strength across metrics.
